Vaxxas secures $3.2m from US for COVID patch project

Vaxxas, a Brisbane-based clinical-stage biotechnology company commercialising a needle-free vaccination platform, has secured $3.2 million from the United States Biomedical Advanced Research and Development Authority (BARDA) to accelerate the advancement of its high-density microarray patch…